Lionco Pharmaceutical Group Co Ltd
SSE:603669
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.79
8.71
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Lionco Pharmaceutical Group Co Ltd
Pre-Tax Income
Lionco Pharmaceutical Group Co Ltd
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lionco Pharmaceutical Group Co Ltd
SSE:603669
|
Pre-Tax Income
-ÂĄ114.5m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Pre-Tax Income
ÂĄ5.7B
|
CAGR 3-Years
20%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Pre-Tax Income
ÂĄ2.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
8%
|
CAGR 10-Years
17%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Pre-Tax Income
ÂĄ8.5B
|
CAGR 3-Years
40%
|
CAGR 5-Years
5%
|
CAGR 10-Years
14%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Pre-Tax Income
ÂĄ6.3B
|
CAGR 3-Years
28%
|
CAGR 5-Years
2%
|
CAGR 10-Years
7%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Pre-Tax Income
ÂĄ4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
218%
|
CAGR 10-Years
N/A
|
|
Lionco Pharmaceutical Group Co Ltd
Glance View
Lionco Pharmaceutical Group Co., Ltd. engages in the sale of chemical drug and antibiotic agents. The company is headquartered in Shannan, Xizang and currently employs 678 full-time employees. The company went IPO on 2015-05-28. is a China-based company principally engaged in the research and development, production and sales of chemical prescription medicine. The firm's products are mainly categorized in to three areas: parenteral nutrition agents, anti-infectious agents and digestive system agents. The lead product of its parenteral nutrition agents is Glutamine for injection; its anti-infectious agents include Cefodizime sodium for injection and Cefathiamidine for injection, among others; its digestive system agents include Omeprazole Sodium for injection and others. The firm operates its business in domestic market.
See Also
What is Lionco Pharmaceutical Group Co Ltd's Pre-Tax Income?
Pre-Tax Income
-114.5m
CNY
Based on the financial report for Sep 30, 2025, Lionco Pharmaceutical Group Co Ltd's Pre-Tax Income amounts to -114.5m CNY.
What is Lionco Pharmaceutical Group Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 3Y
-9%
Over the last year, the Pre-Tax Income growth was -11%. The average annual Pre-Tax Income growth rates for Lionco Pharmaceutical Group Co Ltd have been -9% over the past three years .